Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.


SCAGLIOTTI G., PARK K., PATIL S., ROLSKI J., Goksel T. , MARTINS R., ...More

European journal of cancer (Oxford, England : 1990), vol.45, pp.2298-303, 2009 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2009
  • Doi Number: 10.1016/j.ejca.2009.04.033
  • Title of Journal : European journal of cancer (Oxford, England : 1990)
  • Page Numbers: pp.2298-303
  • Keywords: Cisplatin, Gemcitabine, NSCLC, Pemetrexed, Histology, Survival, Toxicity, 1ST-LINE TREATMENT, TRIAL, CHEMOTHERAPY, CARBOPLATIN, VINORELBINE, DOCETAXEL, COMBINATION, MULTICENTER, PACLITAXEL, REGIMENS